Table 1.
Clinical and genomic profile of 735 glioma patients involved in the study.
| Characteristics | Complete Dataset | LGGs | HGGs | |
|---|---|---|---|---|
| Grade-II | Grade-III | Grade-IV | ||
| No. of patients | 735 | 181 (24.63%) | 205 (27.89%) | 349 (47.48%) |
| Median overall survival | 761.26 | 1128 | 842.23 | 532.45 |
| No. of deaths | 385 (52.38%) | 24 (13.26%) | 59 (28.78%) | 302 (86.53%) |
| Age | 49.65 | 40.37 | 45.687 | 56.79 |
| Gender | ||||
| Male | 427 (58.10%) | 99(54.70) | 116 (56.59%) | 212 (60.74%) |
| Female | 308 (41.90%) | 82 (45.30%) | 89 (43.41%) | 137 (39.26%) |
| IDH mutation | ||||
| Wildtype | 333 (52.61%) | 14 (7.82%) | 57 (27.80%) | 262 (93.91%) |
| Mutant | 330 (52.13%) | 165 (92.18%) | 148 (72.20%) | 17 (6.09%) |
| NA | 72 | 2 | 0 | 70 |
| 1p19q mutation | ||||
| Wildtype | 201 (60.91%) | 96 (53.04) | 88 (42.93%) | 17 (100%) |
| Mutant | 129 (39.09) | 69 (38.12) | 60 (29.27%) | 0 |
Table entries are either means or the number of patients (percentage distribution in parentheses). IDH: isocitrate dehydrogenase; 1p/19q: deletion of chromosome arm 1p and/or 19q. Percentage for IDH calculated using only the number of patients having the corresponding status available.